Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma

March 16, 2017, The JAMA Network Journals

Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study published online by JAMA Ophthalmology.

The advent of intravitreous (in the vitreous, the fluid behind the lens in the eye) anti-vascular endothelial growth factor (VEGF) injections to treat common causes of vision loss, such as exudative (wet) age-related macular degeneration (AMD) and has improved visual outcomes for many patients. Intravitreous injections of anti-VEGF agents may increase the risk of elevated intraocular pressure (IOP); however, the risk of developing moderate to advanced glaucoma requiring has been unclear.

Brennan D. Eadie, M.D., Ph.D., of the University of British Columbia, Vancouver, and colleagues conducted a study that included patients who had received intravitreous bevacizumab injections for exudative . Cases were identified using glaucoma surgical codes for various procedures. For each case, 10 controls were identified; the number of intravitreous bevacizumab injections received per year was determined for both cases and controls.

Seventy-four cases of glaucoma surgery and 740 controls were identified. The researchers found that seven or more injections were associated with a significantly higher risk of glaucoma surgery.

"Clinicians should be aware of the potential association of repeated, recent intravitreous anti-VEGF injections for diseases, such as exudative AMD, with subsequent need for glaucoma surgery," the authors write.

Explore further: Topical dorzolamide-timolol beneficial in neovascular AMD

More information: JAMA Ophthalmol. Published online March 16, 2017.DOI: 10.1001/jamaophthalmol.2017.0059

Related Stories

Topical dorzolamide-timolol beneficial in neovascular AMD

February 26, 2016
(HealthDay)—Topical dorzolamide hydrochloride-timolol appears to reduce central subfield thickness and subretinal fluid in eyes of patients with neovascular age-related macular degeneration (AMD) and incomplete response ...

Mayo Clinic detective work shows possible side effect in macular degeneration drug

October 24, 2011
Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure ...

Bevacizumab, triamcinolone up outcome after cataract surgery

March 9, 2016
(HealthDay)—For patients undergoing cataract surgery, both bevacizumab and triamcinolone administered at the time of surgery correlate with improvements in visual acuity (VA), but only triamcinolone is associated with sustained ...

New study pinpoints biochemical mechanism underlying fibrosis following glaucoma surgery

May 17, 2013
The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial ...

Moderate interobserver agreement for glaucoma software

March 7, 2017
(HealthDay)—There is moderate interobserver agreement among glaucoma specialists using two glaucoma progression software packages, according to a study published online Feb. 23 in JAMA Ophthalmology.

Experimental drug shows promise for sight-stealing eye condition

January 19, 2017
An experimental drug may one day make treatment simpler for patients suffering from vision-threatening age-related macular degeneration, researchers say.

Recommended for you

Older adults with small social networks less likely to get cataract surgery

March 9, 2018
Close family relationships and a strong social network may help older adults see the world better—literally.

A retinal implant that is more effective against blindness

March 9, 2018
EPFL researchers have developed a new type of retinal implant for people who have become blind due to the loss of photoreceptor cells in their retinas. The implant partially restores their visual field and can significantly ...

New imaging technique could improve the diagnosis, treatment of glaucoma

March 7, 2018
The National Eye Institute, part of the National Institutes of Health, projects the number of Americans affected by glaucoma will more than double between 2010 and 2050, from 2.7 million to 6.3 million.

New gene therapy corrects a form of inherited macular degeneration in canine model

March 5, 2018
Researchers from the University of Pennsylvania have developed a gene therapy that successfully treats a form of macular degeneration in a canine model. The work sets the stage for translating the findings into a human therapy ...

New insights into how the retina processes orientation

February 26, 2018
In a study published in Nature Communications, Northwestern Medicine scientists detail the discovery of two types of cells in the retina that determine horizontal or vertical orientation, and demonstrated for the first time ...

Glaucoma study finds brain fights to preserve vision

February 23, 2018
A team of researchers, led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.